PPPA (drug): Difference between revisions
diphenylmethane |
|||
Line 34: | Line 34: | ||
}} |
}} |
||
'''PPPA''', or '''3-phenoxy-3-phenylpropan-1-amine''', is a [[drug]] which is described as an [[antidepressant]].<ref name="LemkeWilliams2008">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA414|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6879-5|pages=414–}}</ref> It was derived by [[Eli Lilly]] from the [[antihistamine]] [[diphenhydramine]], a [[ |
'''PPPA''', or '''3-phenoxy-3-phenylpropan-1-amine''', is a [[drug]] which is described as an [[antidepressant]].<ref name="LemkeWilliams2008">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA414|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6879-5|pages=414–}}</ref> It was derived by [[Eli Lilly]] from the [[antihistamine]] [[diphenhydramine]], a [[diphenylmethane]] derivative with additional properties as a [[selective serotonin reuptake inhibitor]] (SSRI), and has been the basis for the subsequent discovery of a number of other antidepressant drugs.<ref name="Lopez-MunozAlamo2011">{{cite book|author1=Francisco Lopez-Munoz|author2=Cecilio Alamo|title=Neurobiology of Depression|url=https://books.google.com/books?id=lmXRBQAAQBAJ&pg=PA132|date=9 September 2011|publisher=CRC Press|isbn=978-1-4398-3850-1|pages=132–}}</ref><ref name="FischerGanellin2010">{{cite book|author1=Janos Fischer|author2=C. Robin Ganellin|title=Analogue-based Drug Discovery II|url=https://books.google.com/books?id=h2Kd8ci4Ln8C&pg=PA282|date=24 August 2010|publisher=John Wiley & Sons|isbn=978-3-527-63212-1|pages=35, 282, 284}}</ref><ref name="Sneader2005">{{cite book|author=Walter Sneader|title=Drug Discovery: A History|url=https://books.google.com/books?id=jglFsz5EJR8C&pg=PA416|date=31 October 2005|publisher=John Wiley & Sons|isbn=978-0-470-01552-0|pages=416–417}}</ref> |
||
==List of PPPA derivatives== |
==List of PPPA derivatives== |
Revision as of 19:05, 26 December 2023
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C15H17NO |
Molar mass | 227.307 g·mol−1 |
3D model (JSmol) | |
| |
|
PPPA, or 3-phenoxy-3-phenylpropan-1-amine, is a drug which is described as an antidepressant.[1] It was derived by Eli Lilly from the antihistamine diphenhydramine, a diphenylmethane derivative with additional properties as a selective serotonin reuptake inhibitor (SSRI), and has been the basis for the subsequent discovery of a number of other antidepressant drugs.[2][3][4]
List of PPPA derivatives
- Atomoxetine ((3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine) — NRI[1]
- Fluoxetine (N-methyl-3-(4-(trifluoromethyl)phenoxy)-3-phenylpropan-1-amine) — SSRI[2]
- N-Methyl-PPPA (N-methyl-3-phenoxy-3-phenylpropan-1-amine) — SNRI[2][4]
- Nisoxetine (N-methyl-3-(2-methoxyphenoxy)-3-phenylpropan-1-amine) — NRI[1]
- Norfluoxetine (3-(4-(trifluoromethyl)phenoxy)-3-phenylpropan-1-amine) — SSRI[3]
- Seproxetine ((S)-3-(4-(trifluoromethyl)phenoxy)-3-phenylpropan-1-amine) — SSRI[5]
Structurally related drugs include dapoxetine, duloxetine, edivoxetine, femoxetine, paroxetine, reboxetine, and viloxazine, all of which act, similarly, as monoamine reuptake inhibitors, and most of which are, again similarly, antidepressants.[1][3]
Zimelidine is an antidepressant and SSRI which was derived from the antihistamine pheniramine, which, similarly to its analogues brompheniramine and chlorpheniramine, possesses SNRI properties.[4] Fluvoxamine, another antidepressant and SSRI, was developed from the antihistamine tripelennamine, which possesses SNDRI actions.[6]
See also
References
- ^ a b c d Thomas L. Lemke; David A. Williams (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 414–. ISBN 978-0-7817-6879-5.
- ^ a b c Francisco Lopez-Munoz; Cecilio Alamo (9 September 2011). Neurobiology of Depression. CRC Press. pp. 132–. ISBN 978-1-4398-3850-1.
- ^ a b c Janos Fischer; C. Robin Ganellin (24 August 2010). Analogue-based Drug Discovery II. John Wiley & Sons. pp. 35, 282, 284. ISBN 978-3-527-63212-1.
- ^ a b c Walter Sneader (31 October 2005). Drug Discovery: A History. John Wiley & Sons. pp. 416–417. ISBN 978-0-470-01552-0.
- ^ David G. Watson (9 February 2011). Pharmaceutical Chemistry. Elsevier Health Sciences. pp. 1061–. ISBN 978-0-7020-4850-0.
- ^ David Healy (1 June 2004). Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. NYU Press. pp. 295–. ISBN 978-0-8147-7300-0.
Further reading
- Wong DT, Bymaster FP, Engleman EA (1995). "Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication". Life Sci. 57 (5): 411–41. doi:10.1016/0024-3205(95)00209-o. PMID 7623609.